Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven glioblastoma multiforme with evidence of epidermal growth factor receptor (EGFR) expression on tumor cell surfaces
• * No astrocytoma, anaplastic astrocytoma, or oligodendroglioma
• * No infratentorial or multifocal tumor
• Recurrence or progression following at least one prior therapy
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 60-100%
• Life expectancy:
• Greater than 2 months
• Hematopoietic:
• WBC at least 3,000/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin greater than 10 g/dL
• Hepatic:
• Bilirubin no greater than 2.0 mg/dL
• ALT, AST, and alkaline phosphatase no greater than 2.5 times upper limit of normal (ULN)
• Renal:
• Creatinine no greater than 2.0 times ULN
• Other:
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No other medical or psychiatric illness that would preclude study
• No other concurrent malignancy except nonmelanoma skin cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• At least 4 weeks since prior chemotherapy (6 weeks since nitrosoureas)
• Endocrine therapy:
• Concurrent steroid therapy allowed
• Radiotherapy:
• At least 4 weeks since prior radiotherapy
• Surgery:
• Not specified